Nasal delivery

Abstract

A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.

1 - 43 . (canceled) 
     
     
         44 . A method of treating a neurological disorder, consisting of:
 a first step and, separately, a second step;   wherein the first step includes delivering a first substance to the upper posterior, olfactory region of a nasal airway of a subject, which includes the olfactory bulb and the trigeminal nerve of the subject, wherein the first substance comprises from about 1 IU to about 100 IU of an active ingredient; and   wherein the second step includes delivering a second substance to promote transfer of the first substance, wherein the second substance is a liquid and delivered after the first substance.   
     
     
         45 . The method of  claim 44 , wherein the first substance is a powder. 
     
     
         46 . The method of  claim 45 , wherein the first substance is mixed with a bulking agent. 
     
     
         47 . The method of  claim 44 , wherein the first substance is a liquid. 
     
     
         48 . The method of  claim 44 , wherein the first substance includes a thickening agent, which thickens on exposure to moisture. 
     
     
         49 . The method of  claim 48 , wherein the thickening agent comprises one or more of pectin, agar-agar, lignin, algin, gums and cellulose. 
     
     
         50 . The method of  claim 44 , wherein the first substance is administered once daily. 
     
     
         51 . The method of  claim 44 , wherein the first substance is administered twice daily. 
     
     
         52 . The method of  claim 44 , wherein the delivery of the first substance is targeted to provide for one or both of nose-to-brain (N2B) and systemic delivery of the first substance. 
     
     
         53 . The method of  claim 52 , wherein the delivery is targeted to provide for both nose-to-brain (N2B) and systemic delivery of the first substance, and the first substance is formulated to provide for greater N2B delivery than systemic delivery of the first substance. 
     
     
         54 . The method of  claim 44 , wherein the first substance comprises oxytocin. 
     
     
         55 . The method of  claim 44 , wherein the first substance further comprises a decongestant. 
     
     
         56 . The method of  claim 44 , wherein the first substance comprises less than about 20 IU of the active ingredient. 
     
     
         57 . The method of  claim 44 , wherein the first substance comprises less than about 15 IU of the active ingredient. 
     
     
         58 . The method of  claim 44 , wherein the first substance comprises less than about 10 IU of the active ingredient. 
     
     
         59 . The method of  claim 44 , wherein the first substance comprises less than about 5 IU of the active ingredient. 
     
     
         60 . The method of  claim 44 , wherein the first substance comprises from about 3 IU to about 10 IU of the active ingredient. 
     
     
         61 . The method of  claim 44 , wherein the first substance comprises from about 3 IU to about 5 IU of the active ingredient. 
     
     
         62 . The method of  claim 44 , wherein the first substance includes a second active ingredient. 
     
     
         63 . The method of  claim 44 , wherein the neurological disorder comprises Alzheimer's disease, Huntington's disease, Parkinson's disease, dementia, bi-polar disorder, obsessive-compulsive disorder (OCD), autism, eating disorder, addiction, schizophrenia, psychosis, post traumatic stress disorder (PTSD), depression and chronic depression.